A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)

ConclusionsRibociclib administered following radiotherapy is feasible in DIPG and DMG. Increased tumor necrosis may represent a treatment effect. These data warrant further prospective volumetric analyses of tumors with necrosis. Feasibility and stabilization findings support further investigation of ribociclib in combination therapies.Trial registrationNCT02607124.

http://link.springer.com/10.1007/s11060-020-03641-2

Source: Journal of Neuro-Oncology - October 9, 2020 Category: Cancer & Oncology Source Type: research